Global Cryptococcosis Sales Market Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Cryptococcosis Sales Market Report 2024
Market Analysis and InsightsGlobal Cryptococcosis Market
Cryptococcosis, also known as cryptococcal disease, is a potentially fatal fungal disease. It is caused by one of two species; Cryptococcus neoformans and Cryptococcus gattii
Due to the COVID-19 pandemic, the global Cryptococcosis market size is estimated to be worth US$ 54940 million in 2024 and is forecast to a readjusted size of US$ 72550 million by 2034 with a CAGR of 3.6% during the forecast period 2024-2034. Fully considering the economic change by this health crisis, Amphotericin B (Amphocin and Fungizone) accounting for % of the Cryptococcosis global market in 2024, is projected to value US$ million by 2034, growing at a revised % CAGR from 2023 to 2034. While Hospital Pharmacies segment is altered to an % CAGR throughout this forecast period.
The United States Cryptococcosis market is estimated at US$ million in 2024, while China was US$ million. The proportion of the United States is % in 2024, while Chinese percentage was %, and it is predicted that China share will reach % in 2034, trailing a CAGR of % through the analysis period.
The global key manufacturers of Cryptococcosis include Bristol-Myers Squibb, Johnson & Johnson, Abbott, Novartis, Pfizer, Bausch Health, Glenmark, Viamet Pharmaceuticals and Sigmapharm, etc. In 2024, the global top five players occupied for a share approximately % in terms of revenue.
In United States, in terms of sales revenue, in 2024, the top three players hold a share about %, while in China, top three players hold a share nearly %.
Global Cryptococcosis Scope and Market Size
The global Cryptococcosis market is segmented by company, region (country), type and application. Players, stakeholders, and other participants in the global Cryptococcosis market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), type and application for the period 2018-2034.
Segment by Type
Amphotericin B (Amphocin and Fungizone)
Flucytosine (Ancobon)
Fluconazole (Diflucan)
Voriconazole
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
United States
Europe
China
Japan
Southeast Asia
India
Other Regions
Bristol-Myers Squibb
Johnson & Johnson
Abbott
Novartis
Pfizer
Bausch Health
Glenmark
Viamet Pharmaceuticals
Sigmapharm
Cryptococcosis, also known as cryptococcal disease, is a potentially fatal fungal disease. It is caused by one of two species; Cryptococcus neoformans and Cryptococcus gattii
Due to the COVID-19 pandemic, the global Cryptococcosis market size is estimated to be worth US$ 54940 million in 2024 and is forecast to a readjusted size of US$ 72550 million by 2034 with a CAGR of 3.6% during the forecast period 2024-2034. Fully considering the economic change by this health crisis, Amphotericin B (Amphocin and Fungizone) accounting for % of the Cryptococcosis global market in 2024, is projected to value US$ million by 2034, growing at a revised % CAGR from 2023 to 2034. While Hospital Pharmacies segment is altered to an % CAGR throughout this forecast period.
The United States Cryptococcosis market is estimated at US$ million in 2024, while China was US$ million. The proportion of the United States is % in 2024, while Chinese percentage was %, and it is predicted that China share will reach % in 2034, trailing a CAGR of % through the analysis period.
The global key manufacturers of Cryptococcosis include Bristol-Myers Squibb, Johnson & Johnson, Abbott, Novartis, Pfizer, Bausch Health, Glenmark, Viamet Pharmaceuticals and Sigmapharm, etc. In 2024, the global top five players occupied for a share approximately % in terms of revenue.
In United States, in terms of sales revenue, in 2024, the top three players hold a share about %, while in China, top three players hold a share nearly %.
Global Cryptococcosis Scope and Market Size
The global Cryptococcosis market is segmented by company, region (country), type and application. Players, stakeholders, and other participants in the global Cryptococcosis market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), type and application for the period 2018-2034.
Segment by Type
Amphotericin B (Amphocin and Fungizone)
Flucytosine (Ancobon)
Fluconazole (Diflucan)
Voriconazole
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
United States
Europe
China
Japan
Southeast Asia
India
Other Regions
By Company
Bristol-Myers Squibb
Johnson & Johnson
Abbott
Novartis
Pfizer
Bausch Health
Glenmark
Viamet Pharmaceuticals
Sigmapharm